ARK Genomic Price To Earning vs. Net Asset
| ARKG Etf | USD 25.98 0.55 2.16% |
For ARK Genomic profitability analysis, we use financial ratios and fundamental drivers that measure the ability of ARK Genomic to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well ARK Genomic Revolution utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between ARK Genomic's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of ARK Genomic Revolution over time as well as its relative position and ranking within its peers.
ARK |
The market value of ARK Genomic Revolution is measured differently than its book value, which is the value of ARK that is recorded on the company's balance sheet. Investors also form their own opinion of ARK Genomic's value that differs from its market value or its book value, called intrinsic value, which is ARK Genomic's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ARK Genomic's market value can be influenced by many factors that don't directly affect ARK Genomic's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ARK Genomic's value and its price as these two are different measures arrived at by different means. Investors typically determine if ARK Genomic is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ARK Genomic's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
ARK Genomic Revolution Net Asset vs. Price To Earning Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining ARK Genomic's current stock value. Our valuation model uses many indicators to compare ARK Genomic value to that of its competitors to determine the firm's financial worth. ARK Genomic Revolution is the top ETF in price to earning as compared to similar ETFs. It also is the top ETF in net asset as compared to similar ETFs making up about 56,378,404 of Net Asset per Price To Earning. Comparative valuation analysis is a catch-all technique that is used if you cannot value ARK Genomic by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.ARK Net Asset vs. Price To Earning
Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investors monitor daily. Holding a low PE stock is less risky because when a company's profitability falls, it is likely that earnings will also go down as well. In other words, if you start from a lower position, your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit.
ARK Genomic |
| = | 41.86 X |
Generally speaking, the Price to Earnings ratio gives investors an idea of what the market is willing to pay for the company's current earnings.
Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.
ARK Genomic |
| = | 2.36 B |
Net Asset is the value used in calculating NAV of a fund. NAV (or Net Asset Value) is computed once a day based on the formula that uses closing prices of all positions in the fund's portfolio.
ARK Net Asset Comparison
ARK Genomic is currently under evaluation in net asset as compared to similar ETFs.
ARK Genomic Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in ARK Genomic, profitability is also one of the essential criteria for including it into their portfolios because, without profit, ARK Genomic will eventually generate negative long term returns. The profitability progress is the general direction of ARK Genomic's change in net profit over the period of time. It can combine multiple indicators of ARK Genomic, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
The fund is an actively-managed exchange-traded fund that will invest under normal circumstances primarily in domestic and foreign equity securities of companies across multiple sectors, including healthcare, information technology, materials, energy and consumer discretionary, that are relevant to the funds investment theme of the genomics revolution . Ark Genomic is traded on BATS Exchange in the United States.
ARK Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on ARK Genomic. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of ARK Genomic position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the ARK Genomic's important profitability drivers and their relationship over time.
Use ARK Genomic in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if ARK Genomic position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ARK Genomic will appreciate offsetting losses from the drop in the long position's value.ARK Genomic Pair Trading
ARK Genomic Revolution Pair Trading Analysis
The ability to find closely correlated positions to ARK Genomic could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace ARK Genomic when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back ARK Genomic - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling ARK Genomic Revolution to buy it.
The correlation of ARK Genomic is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as ARK Genomic moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if ARK Genomic Revolution moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for ARK Genomic can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your ARK Genomic position
In addition to having ARK Genomic in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Small Cap ETFs Thematic Idea Now
Small Cap ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Small Cap ETFs theme has 167 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Small Cap ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Trending Equities. You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.
To fully project ARK Genomic's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of ARK Genomic Revolution at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include ARK Genomic's income statement, its balance sheet, and the statement of cash flows.